Workflow
全流通
icon
Search documents
境外发行证券和上市备案情况表(截至2026年1月23日) :3家补充材料要求
Sou Hu Cai Jing· 2026-01-26 06:03
四、请说明本次拟参与"全流通"股东所持股份是否存在被质押、冻结或其他权利瑕疵的情形。 2026年1月23日晚,中国证监会3家企业出具了补充材料要求,具体如下: 1、曦华科技(赴港上市) 请你公司补充说明以下事项,请律师核查并出具明确的法律意见: 一、请说明备案材料对控股股东认定结果不一致的原因及认定标准,并就控股股东的认定情况出具明确结论性意见。 二、请说明最近12个月内新增股东入股价格的定价依据及公允性,该等入股价格之间存在差异的原因及其合理性以及税费缴纳情况,是否存在入股对价异 常,并就是否存在利益输送出具明确结论性意见。 三、请说明员工持股平台办理工商变更登记手续的进展情况。 2、臻驱科技(赴港上市) (2)列表说明发行人历次增资及股权转让价格、定价依据,同一批次价格不一致的应说明合理性、是否存在利益输送,零对价转让的应说明交易真实性、对 价公允性,约定价格与实际支付价格不一致的应说明具体原因; (3)就发行人设立及历次股权变动是否合法合规出具结论性意见。 二、请说明 (1)沈捷及其控制的主体合计控制超过30%的表决权,是否均应按照《监管规则适用指引——境外发行上市类第2号》(以下简称《监管指引第2号》 ...
臻驱科技拟港股上市 中国证监会要求补充说明国有股标识办理进展情况等
Zhi Tong Cai Jing· 2026-01-23 12:28
Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for three companies, including Zhenqu Technology, which is seeking to list on the Hong Kong Stock Exchange. The CSRC has requested clarifications on various legal and compliance matters related to the company's shareholding structure and corporate governance [1][2]. Group 1: Regulatory Requirements - Zhenqu Technology is required to provide details on the compliance of shareholding arrangements involving key individuals and the legality of past capital increases and share transfers [1][2]. - The company must clarify the impact of special shareholder rights on control and provide information on major shareholders holding over 5% of shares [2]. - The CSRC has requested a review of the company's stock incentive plans to ensure there are no conflicts of interest or improper benefits [2]. Group 2: Business Operations - Zhenqu Technology is a technology-driven supplier of electric control solutions, primarily targeting the electric vehicle sector, focusing on efficient and reliable vehicle performance [3]. - According to Frost & Sullivan, Zhenqu Technology holds leading positions in the Chinese market for various electric control solutions, ranking first in the main drive power bricks and third in dual motor controllers as of September 30, 2025 [4].
汉森软件拟港股上市 中国证监会要求补充说明募集资金用途等事项
Zhi Tong Cai Jing· 2025-12-19 12:38
Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for overseas listing applications, specifically for Hansen Software, which must clarify the use of raised funds and the proportion of domestic and H shares before and after the "full circulation" [1][2] - Hansen Software has submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan Securities (Hong Kong) and CITIC Securities acting as joint sponsors [1] - Hansen Software is recognized as the leading independent supplier of printing control systems globally, according to Frost & Sullivan, based on projected revenue for 2024 [3] Group 2 - The CSRC has requested detailed explanations regarding the issuance plan, including consistency between the filing report and the prospectus, and any necessary updates to the fundraising plan if there are discrepancies [2] - The company must clarify whether the raised funds will involve overseas investments and confirm compliance with relevant approval or filing procedures [2] - Hansen Software is required to provide updates on various matters, including the progress of deregistration of its value-added telecommunications business and any disputes related to employee equity buybacks that may affect the application for "full circulation" [2]
镁信健康 IPO收证监会备案反馈!直指资质合规、数据安全、股权激励等关键问题
Sou Hu Cai Jing· 2025-10-11 05:00
Core Viewpoint - The company, Meixin Health, is facing significant challenges in its IPO journey due to regulatory scrutiny, financial losses, and ongoing legal disputes, which have raised concerns about its compliance and business model sustainability [1][12][19]. Regulatory Compliance - The China Securities Regulatory Commission (CSRC) has requested Meixin Health to address five core compliance issues before proceeding with its IPO, including business qualifications, data security, stock incentive plans, shareholder rights, and core business model disclosures [2][3][4]. Financial Performance - Meixin Health has reported cumulative losses exceeding 800 million RMB over three years, with cash reserves plummeting by 92% from 22.01 billion RMB in 2021 to just 1.66 billion RMB by April 2025 [4][9][11]. - The company's revenue has shown growth, with projected revenues of 10.69 billion RMB, 12.55 billion RMB, and 20.35 billion RMB for 2022, 2023, and 2024 respectively, reflecting a compound annual growth rate of approximately 38% [4][5]. Business Model and Revenue Streams - The company's main revenue comes from two core business segments: "Smart Drug Solutions" and "Smart Insurance Solutions," which together account for over 95% of total revenue [6][7]. - The "Smart Drug Solutions" segment has faced challenges due to low profit margins, while the "Smart Insurance Solutions" segment has maintained higher margins, increasing from approximately 72% in 2022 to 81.5% in 2024 [7][8]. Legal and Reputational Risks - Meixin Health is embroiled in a legal dispute with Tianxiao Technology, which has accused it of misappropriating trade secrets, potentially impacting its reputation and compliance standing [19][26]. - The ongoing legal issues pose a challenge for the company as it seeks to establish credibility with investors and regulators during its IPO process [26]. Market Environment and Financing Challenges - The company has experienced a slowdown in financing activities, with a significant drop in capital raised from 21.3 billion RMB in 2021 to just 1.78 billion RMB in early 2023, reflecting a tightening capital market environment [17][18]. - Increased reliance on debt financing has raised concerns about financial sustainability, especially given the company's ongoing operational losses [10][17]. Industry Trends - The "Huiminbao" insurance product, a key revenue source for Meixin Health, is facing growth challenges and rising claims, leading to concerns about its long-term viability and potential "death spiral" risks [14][15][16]. - Regulatory scrutiny of innovative insurance products, particularly those related to high-cost medications, has intensified, creating additional compliance challenges for the company [12][13].
港股异动丨汇通达网络逆势收涨5.65% 今日将公布财报
Ge Long Hui· 2025-08-28 08:53
Core Viewpoint - The stock of HuTongDa Network (9878.HK) rose by 5.65% to HKD 16.08, despite the overall decline in the Hong Kong stock market, with a trading volume of HKD 114 million and a market capitalization of HKD 9.046 billion. The company is set to release its interim results for the six months ending June 30, 2025, after the market closes today [1]. Group 1 - HuTongDa Network is expected to achieve steady revenue growth for the full year 2025, according to a report from Citigroup [1]. - The company has proactively reduced low-margin business segments following a strategic adjustment last year, which is anticipated to significantly enhance profit margins this year [1]. - The improvement in the company's profitability path is clear, affirming a positive trend in its fundamentals, leading to a "Buy" rating with a target price of HKD 23 [1].
凯诘电商拟赴港IPO,证监会要求说明多项情况
Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Shanghai Kaijie E-commerce Co., Ltd. (Kaijie E-commerce) to provide supplementary information regarding its previous listing attempts and current plans for A-share listing, amid a backdrop of declining financial performance [1][2][3]. Financial Performance - Kaijie E-commerce reported revenues of approximately 1.829 billion yuan, 1.723 billion yuan, and 1.699 billion yuan for the years 2022, 2023, and 2024, respectively, indicating a continuous decline in revenue [4]. - The company's net profits for the same years were approximately 86 million yuan, 68 million yuan, and 60 million yuan, also reflecting a downward trend [4]. - Revenue from the top five customers accounted for 20.8%, 25.1%, and 26.6% of total revenue in 2022, 2023, and 2024, respectively [4]. - The largest customer contributed 16.7%, 18.6%, and 21.7% of total revenue for the years ending December 31, 2022, 2023, and 2024, respectively [4]. Listing and Regulatory Requirements - The CSRC has mandated Kaijie E-commerce to clarify its previous listing attempts on the National Equities Exchange and Quotations (NEEQ) and the reasons for its withdrawal from the A-share listing process [2][3]. - The company had previously listed on the NEEQ in May 2016 and voluntarily delisted in May 2019, with two subsequent A-share listing applications being withdrawn [3]. - The CSRC requires a legal opinion on whether the proposed shareholders' shares are subject to any pledges, freezes, or other rights defects [3]. Business Operations and Strategy - Kaijie E-commerce is a digital retail solution provider, ranked as the fifth largest in China by GMV in 2024 and the largest O2O digital retail solution provider [4]. - The company aims to use the funds raised from its listing for strategic business expansion, innovation, upgrading digital capabilities, strengthening its technical team and infrastructure, and expanding overseas, particularly in Southeast Asia and Europe [5].